Adam Schechter

Chairman
President and CEO, Labcorp

Global business leader Adam Schechter became chief executive officer of Labcorp (NYSE: LH) on Nov. 1, 2019, and chairman on May 13, 2020. Prior to that, Schechter was named lead independent director in January of 2019 after serving on the board since 2013.

A highly respected healthcare executive with a deep understanding of the U.S. and global environments, Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president and president of global human health and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck’s medicines and vaccines were available to people around the world, led a large global organization across the spectrum of commercial operations, transformed Merck’s commercial model and led the integration of Merck and Schering-Plough. He held a number of professional, managerial and executive roles with the company. Prior to his most recent role from 2010 to 2018 as president of global human health, Merck’s global pharmaceuticals and vaccines business, Schechter served as president of the global pharmaceutical business from 2007 to 2010. Before that, he led Merck’s U.S. pharmaceutical business. He began his career with Merck in 1988 as a sales representative.

Schechter, 57, is also the board chair for Water.org, chair of the Corporate Advisory Council of the National Alliance for Hispanic Health, and executive advisor to the Healthy Americas Foundation. He holds a Bachelor of Arts degree in biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021. Previously, he served on the boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company.

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through unparalleled diagnostics and drug development capabilities, the company provides insights and accelerates innovations to improve health and improve lives. With more than 70,000 employees, Labcorp serves clients in more than 100 countries. Labcorp reported revenue of $14 billion in 2020. It has been named to Fortune’s List of World’s Most Admired Companies, Fast Company’s List of The World’s Most Innovative Companies, and earned the designation as a Best Place to Work for LGBTQ Equality by the Human Rights Campaign Foundation.